DDInter1355 DDInter1822
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The
Aminoglycosides, many of which are derived directly from _Streptomyces_ spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic _Pseudomonas aeruginosa_ infections in cystic fibrosis patients, as _P. aeruginosa_ is notoriously inherently resistant to many antibiotics.[A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria.[L32744, L32749] Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.[A232294, A232349, L32739, L32749] Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).[L32739, L32744, L32749]
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Paromomycin
Paromomycin {u} (Compound) resembles {v} (Compound) Tobramycin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Gentamicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neomycin
Neomycin {u} (Compound) resembles {v} (Compound) Paromomycin
Paromomycin {u} (Compound) resembles {v} (Compound) Tobramycin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Gentamicin {u} (Compound) resembles {v} (Compound) Tobramycin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Gentamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neomycin
Neomycin {u} (Compound) resembles {v} (Compound) Tobramycin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indomethacin
Indomethacin {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Tobramycin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lactulose
Lactulose {u} may cause a minor interaction that can limit clinical effects when taken with {v} Neomycin
Neomycin {u} (Compound) resembles {v} (Compound) Tobramycin
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Tobramycin (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Paromomycin (Compound) and Paromomycin (Compound) resembles Tobramycin (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin (Compound) resembles Kanamycin (Compound) and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Tobramycin (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin (Compound) resembles Paromomycin (Compound) and Paromomycin (Compound) resembles Tobramycin (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Tobramycin (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Gentamicin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin (Compound) resembles Tobramycin (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin (Compound) resembles Tobramycin (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Tobramycin (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Tobramycin (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a minor interaction that can limit clinical effects when taken with Neomycin and Neomycin (Compound) resembles Tobramycin (Compound)